Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double Dose Intensive Chemo-Radiotherapy with Stem Cell Rescue for Neuroblastoma and Sarcomas
NCT00165139Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 1996
- Primary completion
- Nov 2000
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine, cyclophosphamide, doxorubicin, etoposide, cisplatin and 3 more in neuroblastoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Toxicity and Feasibility of Double Dose Chemo-Radiotherapy at 5 years. Started Jan 1996; status: completed.
02
Drugs
vincristinecyclophosphamidedoxorubicinetoposidecisplatin
03
Conditions
neuroblastomaEwing sarcomanon-rhabdomyosarcoma soft tissue sarcoma (NRSTS)
Beyond the preview
Go deeper on NCT00165139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165139.